DIA 2026 · Jun 14–18 · Philadelphia
AuroraPrime · DIA 2026 strategic prep
AuroraPrime · DIA 2026 主舞台战略准备
DIA 2026 — Vendor Presence at the ConferenceDIA 2026 大会厂商出席情况
9 AI regulatory authoring & study design vendors confirmed presenting at DIA 2026 (Jun 14–18, Philadelphia) — compared to AuroraPrime.
9 家 AI 监管文档撰写与研究设计厂商已确认在 DIA 2026（6 月 14–18 日，费城）发表演讲，与 AuroraPrime 对比分析。
Presenting at DIA 2026
DIA 2026 出席厂商
Plus AuroraPrime
不含 AuroraPrime
All DIA 2026 presenters全部 DIA 2026 出席厂商
- Artos AIArtos AIAI-nativeAI 原生
AI Isn't About Generating Documents, it's About Generating Data
- CollateCollateAI-nativeAI 原生
From Point Solutions to Agentic Platform — How Life Science Companies are Rethinking AI-Driven Document Authoring and Strategy
- DIP — Deep Intelligent PharmaDIP — Deep Intelligent PharmaAI-nativeAI 原生
Accelerate Deep Tech Impact — Mentor Japanese MD/PhDs with Agentic AI from Startup Launch to Physician-Led Trials
- Faro HealthFaro HealthAI-nativeAI 原生
Digital Protocols in Action — Enabling End-to-End Automation in Clinical Development · How Standardized Protocol Data Plus AI Power Patient Centric Studies
- PhaseVPhaseVAI-nativeAI 原生
From Protocol to Submission — The Real-World Impact of AI in Clinical Operations
- Vivpro Corporation (REGAIN)Vivpro Corporation (REGAIN)AI-nativeAI 原生
AI in Action — Scaling Regulatory Document Generation Across R&D
- Weave BioWeave BioAI-nativeAI 原生
The Connected Submission — How AI, Automation, and Intelligence are Changing the Regulatory Ecosystem
- Certara (CoAuthor)Certara (CoAuthor)Incumbent守成派
The Bottleneck Has Moved — Why Successful Gen AI Implementation Isn't Just About Speed
- YseopYseopIncumbent守成派
Design Regulatory Grade AI — Enable Scalable, Consistent Workflows Across Document Types
AI-native
AI 原生
vs 2 platform-incumbent
对比 2 家平台守成派
AI-native vendors (7) · vs 2 incumbentsAI 原生（7）· 对比 2 家守成派
- Artos AIArtos AISan Francisco, CA美国旧金山，CA
AI Isn't About Generating Documents, it's About Generating Data
- CollateCollateUSA美国
From Point Solutions to Agentic Platform — How Life Science Companies are Rethinking AI-Driven Document Authoring and Strategy
- DIP — Deep Intelligent PharmaDIP — Deep Intelligent PharmaSingapore新加坡
Accelerate Deep Tech Impact — Mentor Japanese MD/PhDs with Agentic AI from Startup Launch to Physician-Led Trials
- Faro HealthFaro HealthSan Diego, CA美国圣地亚哥，CA
Digital Protocols in Action — Enabling End-to-End Automation in Clinical Development · How Standardized Protocol Data Plus AI Power Patient Centric Studies
- PhaseVPhaseVCambridge, MA美国剑桥，MA
From Protocol to Submission — The Real-World Impact of AI in Clinical Operations
- Vivpro Corporation (REGAIN)Vivpro Corporation (REGAIN)USA美国
AI in Action — Scaling Regulatory Document Generation Across R&D
- Weave BioWeave BioSan Francisco, CA美国旧金山，CA
The Connected Submission — How AI, Automation, and Intelligence are Changing the Regulatory Ecosystem
Disclosed funding
披露融资合计
Excludes public + undisclosed
不含上市公司与未披露金额
Disclosed funding by vendor (3)各厂商披露融资（3 家）
- Weave BioWeave Bio$36M$36M
The Connected Submission — How AI, Automation, and Intelligence are Changing the Regulatory Ecosystem
- YseopYseop$11M$11M
Design Regulatory Grade AI — Enable Scalable, Consistent Workflows Across Document Types
- Artos AIArtos AI$0.5M$0.5M
AI Isn't About Generating Documents, it's About Generating Data
Direct competitors
直接竞争
End-to-end + AI overlap
端到端 + AI 双重重叠
Direct competitors at DIA 2026DIA 2026 直接竞争对手
- Certara (CoAuthor)Certara (CoAuthor)Incumbent守成派
The Bottleneck Has Moved — Why Successful Gen AI Implementation Isn't Just About Speed
- CollateCollateAI-nativeAI 原生
From Point Solutions to Agentic Platform — How Life Science Companies are Rethinking AI-Driven Document Authoring and Strategy
- YseopYseopIncumbent守成派
Design Regulatory Grade AI — Enable Scalable, Consistent Workflows Across Document Types
Trending Topics from DIA 2026 PresentationsDIA 2026 演讲热词趋势
Keywords extracted from all competitor session titles and abstracts. Chip size reflects how many presentations mention the topic.
从所有竞争对手演讲标题与摘要中提取的关键词，芯片大小反映提及该主题的演讲数量。
Based on 10 competitor sessions at DIA 2026 · chip size = frequency · hover for context基于 DIA 2026 10 场竞争对手演讲 · 芯片大小 = 频次 · 悬停查看上下文
Lifecycle coverage matrix生命周期覆盖矩阵
Six dimensions from study design → HAQ. AuroraPrime is the only row that goes full across every column.
六个维度：从研究设计到响应应答（HAQ）。AuroraPrime 是唯一一行全覆盖。
| Vendor | Study Design 研究设计 | Protocol 方案撰写 | CSR / Med Writing CSR / 医学写作 | eCTD Modules eCTD 模块 | Submission Publishing 递交发布 | HAQ / Lifecycle 应答 / 生命周期 |
|---|---|---|---|---|---|---|
China (alphalifesci.com) · Private | Full | Full | Full | Full | Full | Full |
Paris, France · Series C+ | — | Full | Full | Full | — | Partial |
Princeton, NJ · Public | Partial | Partial | Full | Full | Full | Partial |
USA · Private | — | Partial | Full | Full | — | Partial |
San Francisco, CA · Pre-Seed | — | Partial | Full | Full | — | — |
USA · Private | — | Partial | Full | Full | — | — |
San Francisco, CA · Series A | — | — | Full | Full | Full | Full |
Singapore · Private | Partial | Full | Full | Full | Full | Partial |
San Diego, CA · Private | Full | Full | Partial | — | — | — |
Cambridge, MA · Private | Full | Partial | — | — | — | — |
AuroraPrime vs. closest DIA 2026 peersAuroraPrime vs DIA 2026 最近对手
Radar overlay against Certara (incumbent), Weave Bio (best-funded AI-native), Yseop (regulatory-grade legacy) — all presenting at DIA 2026.
雷达图对比 Certara（守成派）、Weave Bio（融资最高的 AI 原生）、Yseop（监管级老兵）——三者均将在 DIA 2026 发表演讲。
Differentiation themes差异化主题
Strategic claims AuroraPrime can make on stage at DIA 2026; each neutralizes a specific DIA-attending vendor.
AuroraPrime 在 DIA 2026 舞台可主张的差异化论点，每条压制一类出席厂商。
End-to-end
端到端
From study design to eCTD-ready submission, in one AI-native platform
从研究设计到 eCTD 就绪递交的统一 AI 原生平台
Neutralizes at DIA 2026:在 DIA 2026 压制：
AI-native
AI 原生
Designed AI-first in 2024+, not retrofitted on a 2010s platform
2024+ AI 原生设计，非旧平台改造
Neutralizes at DIA 2026:在 DIA 2026 压制：
Demo over slideware
实测演示而非 PPT
Live tools demo today — not a roadmap
实时工具演示——非路线图
Neutralizes at DIA 2026:在 DIA 2026 压制：
Globally regulatory-fluent
全球监管原生
Built for FDA/EMA/PMDA/NMPA — multi-region from day one
FDA/EMA/PMDA/NMPA 多区域监管原生
Neutralizes at DIA 2026:在 DIA 2026 压制：
Right-sized for biotech and pharma
贴合 biotech 与 pharma 的体量
Enterprise-grade governance without 18-month implementation
企业级治理——无需 18 个月实施周期
Neutralizes at DIA 2026:在 DIA 2026 压制：
DIA 2026 — Who Is Presenting at the ConferenceDIA 2026 大会演讲一览
AI-powered document authoring and study design vendors confirmed in the DIA 2026 program (Jun 14–18, Philadelphia). Session links open the official DIA 2026 agenda.
在 DIA 2026 大会（6 月 14–18 日，费城）演讲的 AI 文档生成与研究设计厂商，点击可跳转至 DIA 官方议程页面。
AI Document Generation & Regulatory AuthoringAI 文档生成与监管文件撰写
Jun 15, 2026 · 12:25 PM – 12:55 PM · Innovation Theater 2
AI-Augmented Lifecycle — From Study Design to eCTD-Ready Submission — Featuring AI Tools Demo
This session demonstrates AI across two stages of drug development. Part 1 — AI-augmented Study Startup: from Study Design SSOT through Protocol writing to ICF, showing how AI accelerates upstream design and authoring. Part 2 — AI-orchestrated Authoring and QC across the eCTD document network: from M2.7.3 and M2.7.4 Clinical Summaries to Labeling, and from CMC Module 3 to Labeling — accelerating NDA submission. Through live demos, we show how AI discovers cross-document relationships, propagates upstream changes semantically, and delivers submission-ready coherence with a complete audit trail.
Speaker(s):演讲者：
- Sharon Chen, CEO · AlphaLife Sciences
- William Chen · AlphaLife Sciences
- Cieayrra Boozer · AlphaLife Sciences
Jun 16, 2026 · 11:45 AM – 12:15 PM · Innovation Theater 2
AI Isn't About Generating Documents, it's About Generating Data
The speakers will discuss how AI document generation is often a misunderstood problem. Sponsors focus on finding AI that can get words on a page, but they often lose sight of a broader, cross-functional, data strategy that this needs to fit within in order to achieve significant ROI. This discussion will provide a conversation around strategic adoption of AI and concrete case studies in support of that.
Speaker(s):演讲者：
- Josh Kim · Artos AI
- Sean McNiff · Vertex Pharmaceuticals, Inc.
Jun 16, 2026 · 12:25 PM – 12:55 PM · Innovation Theater 1
Design Regulatory Grade AI — Enable Scalable, Consistent Workflows Across Document Types
Content generation is easy. Delivering outputs that are accurate, traceable, and consistent enough for regulatory submission across diverse document types is not. As teams move beyond CSR into protocol, CMC, and pharmacovigilance workflows, many AI solutions fail to adapt, creating risk around compliance, scalability, and usability. This session explores what regulatory grade AI looks like in practice. Through real workflow examples, we will show how configurable, agentic systems embed compliance and validation behind the scenes while adapting to specific business needs, enabling scalable, submission-ready outputs without compromising control.
Speaker(s):演讲者：
- Jenni Pickett, Head of Medical Writing · Yseop
- Camille Sauder · Yseop
Jun 16, 2026 · 1:05 PM – 1:35 PM · Innovation Theater 1
The Bottleneck Has Moved — Why Successful Gen AI Implementation Isn't Just About Speed
ROI is being redefined as GenAI proliferates the regulatory writing space. While initial focus was solely on speed and accuracy, as solutions mature it's clear that time to first draft isn't the only factor that should be considered when deploying AI within your team. In this session, experts from Certara will explore how AI's rapid evolution is changing the way regulatory teams approach their workflows by pulling from real-world examples from CoAuthor implementations.
Speaker(s):演讲者：
- Nick Brown · Certara
- Christopher Kutzler · Certara
Jun 16, 2026 · 3:15 PM – 3:45 PM · Innovation Theater 1
From Point Solutions to Agentic Platform — How Life Science Companies are Rethinking AI-Driven Document Authoring and Strategy
The first wave of AI in life sciences took a document-by-document approach — one solution for the CSR, another for the IB, another for INDs and regulatory submissions. The result: fragmented tools, duplicated validation efforts, and AI that can't learn across your document ecosystem. There is a better architecture. A single AI platform that understands your internal data — clinical, CMC, safety, quality — and combines it with external regulatory intelligence to author any document type on demand. No bespoke point solutions or re-implementation for every new document class. This session draws on how top-20 pharma and medical device companies are deploying this platform approach today.
Speaker(s):演讲者：
- Surbhi Sarna, Founder & CEO · Collate
Jun 16, 2026 · 12:25 PM – 12:55 PM · Innovation Theater 2
AI in Action — Scaling Regulatory Document Generation Across R&D
AI is no longer a future consideration — it is actively reshaping how regulatory work gets done. This session offers a practical, experience-driven perspective on how to operationalize AI for regulatory document generation. We will demonstrate how REGAIN enables flexible document creation with dynamic sectioning and customizable prompts, empowering authors while maintaining quality and consistency. Attendees will also learn key lessons from a successful collaboration — highlighting the importance of governance, cross-functional alignment, and working as one integrated team to drive adoption and deliver measurable impact across R&D.
Speaker(s):演讲者：
- Joga Gobburu, President · Vivpro Corp
- Angela Winnier · Pfizer
- Tushar Nitave · Vivpro Corp
Jun 15, 2026 · 1:05 PM – 1:35 PM · Innovation Theater 1
The Connected Submission — How AI, Automation, and Intelligence are Changing the Regulatory Ecosystem
Explore how AI-enabled authoring is transforming regulatory content development, delivering measurable improvements in speed, consistency, and quality across submissions. Discuss how process standardization serves as the critical enabler for automation, supporting faster, more scalable submission execution. Understand how connecting authoring, standardization, and automation enables regulatory intelligence, unlocking insights from submission content to support proactive planning and decision making.
Speaker(s):演讲者：
- Brandon Rice, Chief Executive Officer · Weave Bio
- Katie Connelly · Parexel International
AI-Powered Study Design & Clinical ProtocolAI 驱动研究设计与临床方案
Jun 15, 2026 · 10:15 AM – 10:45 AM · Innovation Theater 2
Accelerate Deep Tech Impact — Mentor Japanese MD/PhDs with Agentic AI from Startup Launch to Physician-Led Trials
Japanese MDs and PhDs possess deep tacit knowledge and clinical insights that could transform patient care, yet turning these into successful deep tech startups and physician-led clinical trials remains extremely challenging. This session introduces a powerful new approach that combines structured mentoring with Agentic AI to guide Japanese physician-scientists from idea validation and company founding through to efficient, physician-led clinical development. Participants will discover practical frameworks and real-world examples of how Agentic AI accelerates critical steps — including protocol design, regulatory navigation, and evidence generation — while experienced mentors help bridge the gap between academic excellence and market impact.
Speaker(s):演讲者：
- Shinya Yamamoto · Deep Intelligent Pharma (Singapore) Private Limited
Jun 17, 2026 · 9:15 AM – 9:45 AM · Innovation Theater 1
Digital Protocols in Action — Enabling End-to-End Automation in Clinical Development
Clinical trials still rely heavily on static Word documents to define and communicate protocol intent, creating manual handoffs, data inconsistencies, and delays across every downstream system. This session explores how digital, structured protocols serve as the foundation for end-to-end automation in clinical development, eliminating the translation layer between study design and execution. Through a live demo of the Faro platform, attendees will see how a single structured protocol definition can simultaneously drive automation across multiple workflows — from EDC build to authoring and more.
Speaker(s):演讲者：
- Vivian Dewoskin, Chief Commercial Officer · Faro Health Inc.
Jun 16, 2026 · 10:15 AM – 11:30 AM · Room 111AB
How Standardized Protocol Data Plus AI Power Patient Centric Studies
Clinical trial start-up is often delayed by manual processes, fragmented systems, and inconsistent data. This workshop will explore how biopharmaceutical companies are using AI and interoperable data standards to enable patient centric study designs.
Speaker(s):演讲者：
- William Illis · Novartis
- Vivian Dewoskin, Chief Commercial Officer · Faro Health Inc.
- Nicholas Brooke, Executive Director · The Synergist
- Sahishnu Patel · Synterex
- Prasanna Rao, Chief Products and Innovation Officer · Saama
Jun 17, 2026 · 9:15 AM – 9:45 AM · Innovation Theater 2
From Protocol to Submission — The Real-World Impact of AI in Clinical Operations
As clinical trials grow increasingly complex, relying on historical correlations and rigid fixed designs is no longer viable. This session will discuss the practical application of AI across the clinical lifecycle, from identifying predictive early-derived endpoints to dynamically optimizing site selection and patient recruitment. We will share actionable success stories demonstrating how multimodal AI platforms are currently helping biopharma and CROs navigate regulatory demands for explainability while cutting trial durations by 40%.
Speaker(s):演讲者：
- Raviv Pryluk, Co-Founder & CEO · PhaseV
Source: DIA 2026 Global Annual Meeting program · diaglobal.org agenda数据来源：DIA 2026 年度大会官方议程 · diaglobal.org 议程页
Vendor profiles — DIA 2026 presenters厂商详情 — DIA 2026 出席厂商
One card per confirmed DIA 2026 presenter — positioning, strengths, weaknesses, customers, recent news.
每家已确认参加 DIA 2026 的厂商一张卡片：定位、优势、弱点、客户、近期动态。
Artos AI
San Francisco, CA · founded 2023
美国旧金山，CA · 成立 2023 年
Stage阶段
Pre-Seed
Funding融资
$0.5M
Headcount人数
5–15 (YC W24)
5–15 人（YC W24）
AI platform drafting regulatory submissions (IND, PMA) in minutes by ingesting raw R&D data.
AI 平台：摄入原始研发数据，分钟级生成 IND、PMA 等监管递交草稿。
Strengths优势
- YC W24 pedigree
- AI-native from day one
- Founder credibility (UChicago Medicine, Berkeley)
- Vertex Pharmaceuticals on DIA 2026 panel
- YC W24 出身
- 首日即 AI 原生
- 创始人背景过硬（UChicago Medicine、Berkeley）
- DIA 2026 圆桌邀到 Vertex Pharmaceuticals
Weaknesses弱点
- Tiny team
- No public flagship pharma logo
- Pre-Seed maturity
- 团队规模极小
- 暂无公开的旗舰药企案例
- 处于 Pre-Seed 早期阶段
Customers: Vertex Pharmaceuticals (DIA panel reference)
客户：Vertex Pharmaceuticals（DIA 圆桌引用）
Recent: DIA 2026 #522 IT (Jun 16) with Vertex — 'AI Isn't About Generating Documents, it's About Generating Data'
近期：DIA 2026 #522 IT（6/16）与 Vertex 同台——「AI 不是生成文档，而是生成数据」
AuroraPrime angle: AuroraPrime as 'production-ready, big-pharma-deployed' vs. Artos's 'early-stage YC startup'.
AuroraPrime 切入点：AuroraPrime 主打「可投产、已在大药企落地」，对比 Artos 的「YC 早期初创」。
Yseop
Paris, France · founded ~2007
法国巴黎 · 成立 约 2007 年
Stage阶段
Series C+
Funding融资
$11M
Headcount人数
90+ employees
90+ 名员工
Regulatory-Grade AI for Life Sciences — neuro-symbolic AI for medical and regulatory writing automation with deterministic auditability.
面向生命科学的「监管级 AI」——基于神经符号架构的医学与监管写作自动化，具备确定性可审计能力。
Strengths优势
- Tier-1 pharma logos (Lilly, Sanofi, Novartis, GSK)
- TIME's Best Inventions of 2025
- Hybrid neuro-symbolic AI = strong defensibility
- 27,000+ reports generated per month
- Tier-1 药企案例（Lilly、Sanofi、Novartis、GSK）
- 入选 TIME 2025 最佳发明
- 神经符号混合 AI——壁垒坚实
- 每月生成 27,000+ 份报告
Weaknesses弱点
- Mostly post-data-collection writing
- Composite AI architecture is sophisticated but heavy implementation
- 几乎只覆盖数据收集后的写作
- 复合 AI 架构精巧但实施重
Customers: Eli Lilly, Sanofi, Novartis, GSK
客户：Eli Lilly、Sanofi、Novartis、GSK
Recent: DIA 2026 #525 IT (Jun 16) — 'Design Regulatory Grade AI'; 2025 TIME Best Inventions; 2026 BIG Innovation Award
近期：DIA 2026 #525 IT（6/16）——「Design Regulatory Grade AI」；2025 入选 TIME 最佳发明；2026 获 BIG Innovation Award
AuroraPrime angle: AuroraPrime claims 'true end-to-end including study design' + 'modern AI-native' without legacy symbolic baggage.
AuroraPrime 切入点：AuroraPrime 主打「真正端到端、包含研究设计」+「现代 AI 原生」，无传统符号系统的历史包袱。
Certara (CoAuthor)
Princeton, NJ · founded Public (NASDAQ: CERT)
美国普林斯顿，NJ · 成立 上市公司（NASDAQ: CERT）
Stage阶段
Public
Funding融资
—
Headcount人数
~1,000–2,000+
约 1,000–2,000+ 人
Greater Certainty in Drug Development — model-informed drug development (MIDD), biosimulation, regulatory writing (CoAuthor), and end-to-end drug-development software + services.
「让药物开发更具确定性」——模型驱动药物开发（MIDD）、生物仿真、监管写作（CoAuthor）以及端到端药物开发软件 + 服务。
Strengths优势
- Public-company scale, deep regulatory science credibility
- Owns both authoring (CoAuthor) AND publishing (GlobalSubmit)
- Pinnacle 21 used by FDA itself
- 上市公司规模，监管科学积累深厚
- 同时拥有撰写（CoAuthor）与发布（GlobalSubmit）能力
- Pinnacle 21 被 FDA 自身使用
Weaknesses弱点
- AI bolted-on to 25-year-old modeling-software stack
- Heavy/expensive enterprise deployments
- AI 是嫁接在 25 年历史的建模软件栈之上
- 企业级部署重、成本高
Customers: Most top-100 pharma + biotech, FDA (Pinnacle 21)
客户：大部分 top-100 药企与 biotech、FDA（Pinnacle 21）
Recent: DIA 2026 #527 IT (Jun 16) — 'The Bottleneck Has Moved' (CoAuthor)
近期：DIA 2026 #527 IT（6/16）——「The Bottleneck Has Moved」（CoAuthor）
AuroraPrime angle: AuroraPrime claims (a) AI-native architecture, (b) faster/lighter implementation, (c) modern UX.
AuroraPrime 切入点：AuroraPrime 主打 (a) AI 原生架构、(b) 更快更轻的实施、(c) 现代化 UX。
Collate
USA · founded Private
美国 · 成立 未披露
Stage阶段
Private
Funding融资
—
Headcount人数
Not disclosed
未披露
Single agentic-AI platform that authors any regulatory document on demand by combining internal clinical/CMC/safety/quality data with external regulatory intelligence.
单一 agentic-AI 平台：结合内部临床 / CMC / 安全 / 质量数据与外部监管情报，按需生成任意监管文档。
Strengths优势
- Single platform vs. point solutions narrative
- Top-20 pharma + medical-device deployments claimed
- Founder profile (Surbhi Sarna)
- 单一平台 vs 点状解决方案叙事
- 号称已在 top-20 药企与医疗器械商落地
- 创始人背景过硬（Surbhi Sarna）
Weaknesses弱点
- No upstream study-design coverage
- Public funding / headcount not disclosed
- 上游研究设计未覆盖
- 融资 / 人数未公开
Customers: Top-20 pharma (anonymized), Medical device companies (anonymized)
客户：Top-20 药企（匿名）、医疗器械企业（匿名）
Recent: DIA 2026 #546 IT (Jun 16) — 'From Point Solutions to Agentic Platform'
近期：DIA 2026 #546 IT（6/16）——「From Point Solutions to Agentic Platform」
AuroraPrime angle: AuroraPrime extends the same 'one platform' story upstream into study design — Collate starts at the document.
AuroraPrime 切入点：AuroraPrime 把「单一平台」叙事向上延伸到研究设计——Collate 仍从文档起步。
Vivpro Corporation (REGAIN)
USA · founded Private
美国 · 成立 未披露
Stage阶段
Private
Funding融资
—
Headcount人数
Not disclosed
未披露
REGAIN — AI-powered regulatory document automation, transforming data into submission-ready reports with dynamic sectioning and customizable prompts.
REGAIN——AI 驱动的监管文档自动化，将数据转化为递交就绪报告，支持动态分节与自定义 prompt。
Strengths优势
- Claims 60% of Top-20 pharma as clients
- Pfizer co-presenter at DIA 2026
- Workflow flexibility (dynamic sectioning, prompt customization)
- 宣称已覆盖 Top-20 药企的 60%
- DIA 2026 与 Pfizer 共同演讲
- 工作流灵活（动态分节、prompt 自定义）
Weaknesses弱点
- Founding year / funding not public
- No upstream study design
- 成立年份 / 融资未公开
- 上游研究设计未覆盖
Customers: Pfizer (DIA co-presenter), 60% of Top-20 pharma (claimed)
客户：Pfizer（DIA 共同演讲）、Top-20 药企的 60%（自述）
Recent: DIA 2026 #524 IT (Jun 16) with Pfizer — 'AI in Action — Scaling Regulatory Document Generation Across R&D'
近期：DIA 2026 #524 IT（6/16）与 Pfizer 同台——「AI in Action：在 R&D 规模化生成监管文档」
AuroraPrime angle: AuroraPrime: end-to-end + cross-document propagation; Vivpro REGAIN remains document-by-document.
AuroraPrime 切入点：AuroraPrime：端到端 + 跨文档语义传播；Vivpro REGAIN 仍按单文档生成。
Weave Bio
San Francisco, CA · founded ~2023
美国旧金山，CA · 成立 约 2023 年
Stage阶段
Series A
Funding融资
$36M
Headcount人数
30–60 est.
约 30–60 人
AI-native regulatory platform automating full dossier lifecycle: authoring → review → publishing → response management.
AI 原生监管平台：覆盖 dossier 全生命周期——撰写 → 审阅 → 发布 → 答复管理。
Strengths优势
- Best-funded AI-native regulatory startup ($36M)
- Comprehensive submission lifecycle (IND → NDA → HAQ)
- Parexel CRO partnership
- Strong founder pedigree (Brandon Rice, Ari Caroline)
- AI 原生监管初创中融资额最高（$36M）
- 递交全生命周期完整（IND → NDA → HAQ）
- 与 Parexel CRO 建立合作
- 创始人背景过硬（Brandon Rice、Ari Caroline）
Weaknesses弱点
- Starts at IND/dossier — no protocol/study design
- US-centric, no Asia presence
- 起点在 IND/dossier——不覆盖方案/研究设计
- 以美国为中心，无亚洲布局
Customers: Trace Biosciences, Top 20 Pharma (anonymized), Parexel
客户：Trace Biosciences、Top 20 药企（匿名）、Parexel
Recent: DIA 2026 #425 IT (Jun 15) with Parexel — 'The Connected Submission'; Oct 2025 $20M Series A
近期：DIA 2026 #425 IT（6/15）与 Parexel 同台——「The Connected Submission」；2025 年 10 月完成 $20M A 轮
AuroraPrime angle: AuroraPrime claims 'true end-to-end from study design to eCTD' — Weave starts later.
AuroraPrime 切入点：AuroraPrime 主打「研究设计 → eCTD 真端到端」；Weave 的起点更靠后。
DIP — Deep Intelligent Pharma
Singapore · founded Private
新加坡 · 成立 未披露
Stage阶段
Private
Funding融资
—
Headcount人数
Not disclosed (Sequoia-backed)
未披露（Sequoia 投资）
The 'AI Engine Behind China's Biotech Rise' — automating protocol design, statistical analysis, medical writing, regulatory translation, and submission management.
「驱动中国 biotech 崛起的 AI 引擎」——自动化方案设计、统计分析、医学写作、监管翻译与递交管理。
Strengths优势
- Direct AuroraPrime peer geographically
- Strong NMPA expertise + cross-border CN/JP/EN translation
- Big-pharma logos (Bayer, Merck, Roche)
- Sequoia backing
- 地域上是 AuroraPrime 的直接对位玩家
- NMPA 专业能力强，支持中 / 英 / 日跨境翻译
- 大药企案例（Bayer、Merck、Roche）
- Sequoia 背书
Weaknesses弱点
- Customer claims need scrutiny ('1,000 clients')
- SPA-only website (poor SEO/transparency)
- NMPA-first positioning
- 客户数据存疑（号称「1,000 家」）
- 网站为纯 SPA，SEO 与透明度差
- 定位以 NMPA 优先
Customers: Bayer, Merck, Roche, 1,000+ clients claimed
客户：Bayer、Merck、Roche、号称 1,000+ 客户
Recent: DIA 2026 #401.2 IT (Jun 15) — Agentic AI for Japanese MD/PhD-led trials
近期：DIA 2026 #401.2 IT（6/15）——日本 MD/PhD 主导试验的 Agentic AI
AuroraPrime angle: AuroraPrime: (a) FDA/EMA-first vs. NMPA-first, (b) end-to-end including upstream study design, (c) demo-driven thought leadership at Western audiences.
AuroraPrime 切入点：AuroraPrime：(a) FDA/EMA 优先 vs. NMPA 优先；(b) 端到端含上游研究设计；(c) 面向西方受众做 demo 驱动的 thought leadership。
Faro Health
San Diego, CA · founded Private
美国圣地亚哥，CA · 成立 未披露
Stage阶段
Private
Funding融资
—
Headcount人数
Not disclosed
未披露
The AI platform for accelerated clinical development — digital, structured protocols as the foundation for end-to-end automation from EDC build to authoring.
「加速临床开发的 AI 平台」——数字化、结构化方案作为端到端自动化的基础，覆盖 EDC 搭建到文档撰写。
Strengths优势
- Merck case study published (May 2024 TIRS)
- Jan 2026 TransCelerate Protocol Review Challenge winner
- Quantified ROI ($300M+ savings, 200K patient hours)
- Two DIA 2026 sessions (IT + workshop)
- 已发表 Merck 案例（2024/5 月 TIRS）
- 2026 年 1 月获 TransCelerate Protocol Review Challenge 大奖
- 量化 ROI（节省 $300M+、20 万患者小时）
- DIA 2026 两场（IT + Workshop）
Weaknesses弱点
- Stops at study execution — no CSR/eCTD
- Funding / headcount not public
- 止步于研究执行，不覆盖 CSR / eCTD
- 融资 / 人数未公开
Customers: Merck (published case study), Novartis (DIA workshop co-presenter)
客户：Merck（已发表案例）、Novartis（DIA Workshop 共同演讲）
Recent: DIA 2026 #601 IT (Jun 17) + Workshop #508 (Jun 16, Novartis); Jan 2026 TransCelerate award
近期：DIA 2026 #601 IT（6/17）+ Workshop #508（6/16，Novartis 同台）；2026 年 1 月获 TransCelerate 大奖
AuroraPrime angle: AuroraPrime continues from Faro's structured protocol all the way to eCTD-ready submission; Faro stops at execution.
AuroraPrime 切入点：AuroraPrime 从结构化方案一路贯通到 eCTD 递交；Faro 止步于执行。
PhaseV
Cambridge, MA · founded Private
美国剑桥，MA · 成立 未披露
Stage阶段
Private
Funding融资
—
Headcount人数
Not disclosed
未披露
Causal-ML + GenAI multimodal platform for clinical-development optimization — Trial / Response / Portfolio / ClinOps Optimizers powered by 10M+ patient records.
因果 ML + GenAI 多模态平台：基于 1,000 万+ 患者层级数据，覆盖 Trial / Response / Portfolio / ClinOps Optimizer。
Strengths优势
- 45+ biopharma + CRO customers
- Investor base (Accel, Insight Partners, Viola)
- Causal-ML differentiation = explainability
- Documented 40% trial duration cuts
- 45+ 家 biopharma 与 CRO 客户
- 投资人阵容强（Accel、Insight Partners、Viola）
- 因果 ML 提供可解释性差异化
- 记录在案的试验时长缩短 40%
Weaknesses弱点
- Stops at trial execution — no authoring / submission
- Founder-led, funding round not public
- 止步于试验执行，不覆盖撰写 / 递交
- 创始人主导，融资轮次未公开
Customers: Oramed, Enlivex, EMD Serono, iOMEDICO, Alimentiv, Neurosense
客户：Oramed、Enlivex、EMD Serono、iOMEDICO、Alimentiv、Neurosense
Recent: DIA 2026 #602 IT (Jun 17) — 'From Protocol to Submission — The Real-World Impact of AI'
近期：DIA 2026 #602 IT（6/17）——「从方案到递交：AI 在临床运营的真实影响」
AuroraPrime angle: AuroraPrime carries PhaseV's design output downstream into structured protocol → CSR → eCTD authoring.
AuroraPrime 切入点：AuroraPrime 把 PhaseV 的设计产出向下游延伸：结构化方案 → CSR → eCTD 撰写。